Translating RNA splicing analysis into diagnosis and therapy

Abstract

A large proportion of rare disease patients remain undiagnosed and the vast majority of such conditions remain untreatable whether diagnosed or not. RNA splicing analysis is able to increase the diagnostic rate in rare disease by identifying cryptic splicing mutations and can help in interpreting the pathogenicity of genomic variants. Whilst targeted RT-PCR analysis remains a highly sensitive tool for assessing the splicing effects of known variants, RNA-seq can provide a more comprehensive transcriptome-wide analysis of splicing. Appropriate care should be taken in RNA-seq experimental design since sample quality, processing, choice of library preparation and sequencing parameters all introduce variability. Many bioinformatic tools exist to aid both in the prediction of splicing effects from DNA sequence and in the handling of RNA-seq data for splicing analysis. Once identified, splicing abnormalities may be amenable to correction using antisense oligonucleotide compounds by masking cryptic splice sites or blocking key splice regulatory elements, or by use of alternative corrective technologies such as trans-splicing. A growing number of such drugs have started to enter clinical use, most notably nusinersen for the treatment of spinal muscular atrophy. By bringing together the fields of RNA diagnostics and antisense therapeutics, it is becoming feasible to envisage the development of a truly personalised medicine pipeline. This has already been shown to be possible in the case of milasen, an n=1 bespoke antisense drug, and the growth and convergence of these technologies means that similar therapeutic opportunities should arise in the near future.

More information

Identifiers

ORCID for Andrew Douglas: orcid.org/0000-0001-5154-6714

ORCID for Diana Baralle: orcid.org/0000-0003-3217-4833

Catalogue record

Export record

Altmetrics